It is crucial that the host and intestinal microflora interact and influence each other to maintain homeostasis and trigger pathological processes. Recent studies have shown that transplantation of the murine intestinal content to recipient germ-free mice enables transmission of the donor’s phenotypes, such as low level chronic inflammation associated with lifestyle-related diseases. These findings indicate that intestinal bacteria produce some molecules to trigger pathological signals. However, fecal microbial metabolites that induce obesity and the type II diabetic phenotype have not been fully clarified. Here, we showed that the intestinal bacterial metabolite stercobilin, a pigment of feces, induced proinflammatory activities including TNF-α and IL-1β induction in mouse macrophage RAW264 cells. Proinflammatory stercobilin levels were significantly higher in ob/ob mice feces than in the feces of control C57BL/6 J mice. Moreover, in this study, we detected stercobilin in mice plasma for the first time, and the levels were higher in ob/ob mice than that of C57BL/6 J mice. Therefore, stercobilin is potentially reabsorbed, circulated through the blood system, and contributes to low level chronic inflammation in ob/ob mice. Since, stercobilin is a bioactive metabolite, it could be a potentially promising biomarker for diagnosis. Further analyses to elucidate the metabolic rate and the reabsorption mechanism of stercobilin may provide possible therapeutic and preventive targets.
It is becoming clear that the intestinal microflora and host communicate with each other to regulate homeostasis and sometimes trigger pathophysiological changes1,2. A pioneering study reported that fecal microbiota transplantation enabled transmission of several phenotypes from the donor, including insulin resistance, fat accumulation, obesity, hyperglycemia, hypertriacylglycerolemia, hypercholesterolemia, hypertension, hyperphagia, and low level chronic inflammation3,4. These conditions were negated by the treatment with antibiotics, showing that they originated from fecal microbiota transplantation. However, it is not understood which molecules mediate the transmission of pathophysiological changes from donor to recipient. Additionally, it has been pointed out that the deterioration of intestinal microbiota in humans is related not only to lifestyle-related diseases, including obesity, diabetes, cancer, and cardiovascular diseases, but also to many other diseases, such as dementia5 and mental diseases6. One reason for this is inflammation, which is a common risk factor. Therefore, moderate or low level chronic inflammation induced by bacterial molecules is thought to be a fundamental mechanism for triggering and promoting these disorders because of interactive communication between host and intestinal bacteria.
In addition to 16 s rRNA sequencing, metabolomics analysis is an effective approach to understanding how the host and bacteria communicate in the intestinal environment. It has been revealed that some bioactive intestinal and microbial metabolites were strongly associated with homeostasis and disease etiology. For example, representative volatile organic compounds in the intestinal tract include short-chain fatty acids (SCFAs). SCFAs produced by intestinal fermentation are consumed as an energy source and function as bioactive metabolites for immune regulation, suppression of food intake, and enhancing the intestinal barrier function, which mediates anti-obesity, anti-diabetes, and anti-carcinogenesis effects7,8,9,10,11,12. Moreover, deoxycholate generated by the metabolism of intestinal microbiota induces DNA damage and inflammation, which might play a pivotal role in obesity-associated hepatic carcinogenesis13. Another example is the metabolites of dietary lipid phosphatidylcholine (lecithin), including trimethylamine N-oxide (TMAO) and betaine, whose levels are strongly associated with the pathogenesis of cardiovascular diseases14,15. Of note, TMAO and betaine have proinflammatory activities that induce scavenger receptors on macrophages. Similar to compounds such as deoxycholate, TMAO and betaine, bioactive metabolites have advantages as predictive biomarkers. These “bioactive” biomarkers trigger, initiate, and promote pathological events, and therefore might be useful in the diagnosis in early stage diseases.
Urobilinoids are a naturally occurring bile pigment formed by intestinal bacteria in the heme catabolic pathway16. Heme released from hemoglobin during several pathophysiological states is sequentially converted to biliverdin by hemeoxygenase, then to bilirubin by biliverdin reductase17. Bilirubin diglucuronide formed by uridine diphosphate glucuronosyl transferase (UGT) is secreted from hepatocytes to bile via the MRP2 transporter18. Bilirubin diglucuronide is deconjugated and converted by intestinal bacteria to form urobilinoids, which are a group of metabolites consisting of porphyrin derivative. The four major urobilinoids are urobilinogen, urobilin, stercobilinogen, and stercobilin. Among them, urobilinogen is a major primary urobilinoid, some of which is absorbed in the intestine and transported to the kidney. Then, urobilinogen and its oxidized form, urobilin, are excreted in urine. Another part of urobilinogen is enzymatically reduced by intestinal bacteria to form stercobilinogen. Then, stercobilinogen and its oxidized form, stercobilin, are excreted in feces16. Indeed, some hepatopathies cause pathologically elevated levels of plasma bilirubin. However, the physiological level of bilirubin seems to be beneficial for preventing obesity and diabetes because bilirubin directly binds with peroxisome proliferator-activated receptor alpha (PPARα), and positively drive the fatty acid β-oxidation19. However, although urobilinoids are used to monitor fecal pollution20, few studies addressing the bioactivities in the human body have been published previously.
In this study, we performed metabolomics analyses to determine proinflammatory metabolites in the feces of obese/diabetic model ob/ob mice (Fig. 1A). We found that stercobilin, a urobilinoid, induced proinflammatory activities and was higher in ob/ob feces and plasma compared with those of C57BL/6 J mice. These findings suggest that an elevated level of fecal stercobilin is potentially reabsorbed, systemically circulated in the body, and contributes to low level chronic inflammation in ob/ob mice.
Pathological features of ob/ob mice
The body weight of ob/ob mice was significantly higher than that of C57BL6/J mice for all experimental periods (Fig. 1B). The fecal 16 s rRNA sequence in feces collected at weeks 6 and 22 demonstrated that, as reported by other studies, the number of Firmicutes in ob/ob mice increased with a corresponding decrease in Bacteroidetes in an age-dependent manner (Fig. 1C). Five bacterial family/genus were statistically significance by two-way ANOVA in week or mouse lineage (Table S1). Especially, the ratio of Lachnospiraceae, one of the bacteria of Firmicutes, was markedly higher in ob/ob mice (Table S1). Several fatty liver observations, such as hepatic ballooning degradation and fat droplets, were found in ob/ob mice (Fig. 1D,E). Additionally, adipocyte hypertrophy (Fig. 1F,G) and macrophage infiltration (Fig. 1H,I) were observed in white adipose tissues of ob/ob mice, which was strongly associated with the low-level chronic inflammation. mRNA levels of TNF-α and IL-1β in the WAT of ob/ob mice were, respectively, 17- and 4-fold higher than those of C57BL/6 J mice (Fig. 2A). The iNOS and COX-2 in WAT were also, respectively, 5.4- and 2.2-fold higher than those of C57BL/6 J mice (Fig. 2A). Hepatic gene expression of IL-6 was significantly increased in ob/ob mice compared with C57BL/6 J mice although TNF-α and IL-1β were not markedly increased (Fig. 2B). In contrast, no obvious elevation of inflammatory genes was observed in the colonic mucosa (Fig. 2C). These results suggest that the microbial composition changes and systemic low-level chronic inflammation were induced in ob/ob mice.
Proinflammatory activities of mice fecal aqueous and organic extracts
Fecal extracts prepared by Bligh–Dyer extraction (Fig. 3A) were applied to LC-MS non-target metabolomics. Principal component analysis (PCA) demonstrated that feces samples collected at week 0 were clearly distinguished from others (collected from weeks 6 to 22), which was due to the changeover from breeder chow (CE-2) to experimental chow (AIN-76) during week-1 (when the mice were 4 weeks old) (Fig. S1). In other words, PCA distribution of samples collected at weeks 6 to 22 seemed to be homeostatically converged in PCA score plot (Fig. S1). Since fecal metabolomics directly reflects the diet-dependent change of gut environment, continuous consumption of same diet (AIN-76) enables to eliminate possible interferes in subsequent data analysis. Therefore, feces collected at weeks 10 and 20 were subjected to NF-κB reporter gene assays to evaluate the proinflammatory activities of the fecal extracts. Murine macrophage RAW264 cells transfected with pNL3.2 NF-κB-RE vector were exposed to fecal extracts. The aqueous phase, but not the organic phase, equivalent to 10 mg feces from C57BL/6 J and ob/ob mice collected at week 10 significantly induced NF-κB activation, as determined by relative luminescence units (RLUs) (Fig. 3B). The RLUs induced by the aqueous phase of ob/ob mice was significantly higher than that of C57BL/6 J mice (Fig. 3B). These RLUs were dose-dependently increased by treatment with fecal extracts (Fig. 3C) We observed that the aqueous extract from ob/ob mice feces collected at week 20 also induced stronger NF-κB activation than that of C57BL/6 J mice (Fig. 3D). Additionally, higher levels of RLUs induced by the aqueous phase of ob/ob mice feces were also observed in human colon cancer HCT116 and HT29 cells (Fig. S2). These findings suggest that the aqueous fraction of ob/ob fecal extracts contained potential proinflammatory compounds.
Proinflammatory activities of fractionated fecal aqueous extracts
Because fecal aqueous extracts of ob/ob mice induced strong NF-κB activities, LC-MS analysis was performed to explore the proinflammatory compounds of the extracts. As shown in Fig. 4A, chromatograms were roughly divided to four fractions. These fractions were collected and applied to NF-κB reporter gene assays. It was confirmed that NF-κB activities induced by fecal extracts (crude) from ob/ob mice were significantly higher than those of C57BL/6 J mice (Fig. 4B). Moreover, we found that fraction #2 of ob/ob mice eluted between 8 and 11 min significantly increased NF-κB activity compared with that of C57BL/6 J mice, although other fractions (fractions #1, 3, and 4) showed no difference in induction between the C57BL/6 J and ob/ob groups. A volcano plot revealed that one MS ion peak m/z 595.34 at 9.0 min was extracted as a characteristic MS ion peak in fraction #2 of the ob/ob group (Fig. 4C). To identify the compound (m/z 595.34 at 9.0 min), MS/MS analysis was performed. As shown in Fig. 5, we observed two prominent fragment ions, which were m/z 345.1670 and 470.2452 (Fig. 5A). The molecular formulas of the precursor ion (m/z 595.34) and fragment ions (m/z 345.1670 and 470.2452) were estimated as C33H46N4O6, C19H24N2O4, and C26H35N3O5, respectively. A database search was performed, then this metabolite was predicted as stercobilin. An LC chromatogram and MS and MS/MS spectra were exactly matched to the standard, thus the metabolite was assigned as a stercobilin (Fig. 5B). Although there was some individual variability within the group, the fecal levels of stercobilin in ob/ob mice were obviously higher than those of C57BL/6 J mice at weeks 6–22 (Fig. 5C). Although it was not significant, the plasma levels of stercobilin in ob/ob mice was 1.8-fold higher than those of C57BL/6 J mice (Fig. 5D). These results suggest that stercobilin is a potential biomarker for diabetic/obese model animals.
Proinflammatory activities of stercobilin in RAW264 cells
To confirm the proinflammatory activities of stercobilin, we performed NF-κB reporter gene assay using a stercobilin standard. As a result, stercobilin significantly induced NF-κB reporter gene activities in a dose-dependent manner (Fig. 6A). Additionally, stercobilin significantly induced expression of several inflammation-related genes, including TNF-α, IL-1β, IL-6, iNOS, and COX-2 (Fig. 6B). These results suggest that the higher levels of stercobilin observed in ob/ob mice feces contributed to the low level chronic inflammation in ob/ob mice.
In this study, to explore proinflammatory fecal metabolites in obese/diabetic model ob/ob mice, we performed metabolomics (LC-MS) and bioassay (NF-κB reporter gene assay). Here we showed that levels of stercobilin were higher in ob/ob mice feces and plasma than those of control C57BL/6 J mice. Furthermore, stercobilin induced NF-κB activities and inflammatory gene expression in culture cells. Because bioactive metabolites themselves trigger subsequent pathological events, stercobilin is a potential biomarker for diagnosing disorders at an early stage.
Stercobilin, a brown pigment in feces, is formed by catabolic conversion by intestinal bacteria. Metabolites formed by intestinal bacteria, such as urobilinogen, urobilin, stercobilinogen, and stercobilin, are collectively referred as urobilinoids16. Although the physiological roles of urobilinoids are not understood, the functional roles of bilirubin in the human body has been well studied. For example, in one study, bilirubin showed antioxidative activity via radical scavenging21,22 and in another study, bilirubin reduced adiposity and fatty liver in obese subjects via binding with PPARα19. It is reported that plasma levels of bilirubin are lowered in obese humans23 and negatively correlate with colorectal cancer in people in the United States24. Therefore, bilirubin within the physiologically healthy range seems to play favorable roles to prevent lifestyle-related diseases, although a pathologically elevated level of bilirubin in plasma is reflective of liver disease. However, it is unclear so far whether stercobilin has direct roles in any signaling pathway associated with obesity, diabetes or cancer. Interestingly, in one study, the fecal stercobilin level was significantly lowered (by 40%–45%) in autism spectrum disorder (ASD) model mice compared with sex matched controls25. Additionally, deletion of Chd8, a gene responsible for ASD, induced not only delayed the neurodevelopment directly associated with major ASD symptoms, but also induced slender habitus via inhibition of C/EBPβ-regulating adipogenesis26. These findings suggest that stercobilin is involved in obesity/diabetes mellitus through not only proinflammatory activities but also lipid metabolism in the C/EBPβ pathway. Another study used metabolomics of cecal and liver tissues to show that urobilinoids were elevated in high fat diet-induced obese C57BL/6 N mice27. Therefore, bilirubin formed by host metabolism and urobilinoids formed by intestinal bacteria have a similar chemical structure, but they may show opposite activities in the body. This plausible suggestion is supported by a secondary bile acid, deoxycholate, which is also formed by intestinal bacterial metabolism and is capable of inducing the cell senescence associated with liver carcinogenesis13. Bacterial 16 s rRNA sequencing, a powerful tool to clarify the profile of microflora, has opened new fields and markedly advanced our understanding of the interaction between the host and its bacteria. In the current study, 16 rRNA sequencing analysis revealed that the ratio of Lachnospiraceae, one of the bacteria of Firmicutes, was markedly higher in ob/ob mice (Table S1). Interestingly, it has been reported that intestinal colonization by a Lachnospiraceae contributed to the development of diabetes in germ-free ob/ob mice28. Further analysis must confirm whether Lachnospiraceae has a capacity to produce stercobilin. Therefore, in addition to 16s rRNA sequencing, fecal metabolomics is a crucial approach to discovering the etiology of intestinal microbiota induced pathophysiological alterations of the host.
Intestinal bacterial species, including Bacteroides fragilis, Clostridium ramosum, Clostridium perfringens, and Clostridium difficile, have been shown to catabolize bilirubin to urobilinogen29,30,31,32, although we could not assign these bacterial species in our results (Fig. 1C). Additionally, we detected proinflammatory stercobilin in not only feces but also plasma (Fig. 5D), suggesting the intestinal reabsorption of stercobilin. This absorbability of urobilinoids was found and reported in another study27. Multidrug resistant protein (MRP2) is a transporter for bilirubin diglucuronide excreted into bile and MRP3 is a transporter for bilirubin reabsorption into blood stream33. However, urobilinoid transporters that contribute to the enterohepatic circulation of urobilinoids have not been identified. Several mechanisms that describe how stercobilin is highly produced in ob/ob mice can be speculated, for example, (i) increased heme degradation by hepatopathy, (ii) increased deconjugation of bilirubin diglucuronide by microbial changes and (iii) lowered reabsorption of urobilinogen. However, detailed mechanisms are not understood yet.
The concentration of stercobilin required for the NF-κB activation in RAW264 cells were ~ 1000 times higher than those observed in ob/ob mice plasma. RAW264 cells required ~ μm stercobilin to activate NF-κB, which was “one shot” treatment in in vitro. On the other hand, in a clinical condition and in vivo experiments, it is well known that a low-level but chronic inflammation is strongly associated with life-style related diseases. In the current study, we detected higher levels of plasma stercobilin during an experimental period (Fig. 5D), suggesting a continuous exposure of higher levels of stercobilin to ob/ob mice. Moreover, in our preliminary experiment using C57BL/6 mice, treatment with 10 ppm (0.001%) urobilinogen in drinking water for 8 weeks slightly (3-fold increase) but significantly up-regulated levels of plasma urobilinogen, and inflammatory cytokines including TNF-α, IL-1β, IL-6 in liver, suggesting that urobilinoids potentially induce proinflammatory activities in in vivo, even if the concentration is ~nM order (unpublished observations). Therefore, we must confirm in our further study whether ~nM stercobilin in circulating blood is able to induce a chronic inflammation associated with lifestyle related disease.
Although levels of stercobilin were elevated in the feces in ob/ob mice, some other peaks in LC-MS were significantly higher in C57BL/6 J mice compared with ob/ob mice (Fig. 4C). Among them, one metabolite was identified, 5′-deoxy-5′-(methylthio)adenosine (MTA). It has been reported that MTA showed anti-oxidative activities34. Therefore, a lowering of antioxidative metabolites such as MTA in the intestinal tract could be another mechanism that contributes to low level chronic inflammation in lifestyle-related diseases.
In this study, we investigated intestinal metabolites soluble in aqueous and organic solvent and found that stercobilin was higher in ob/ob mice feces than that of controls, and that it induced moderate proinflammatory activities. Many critical metabolites have been discovered and identified using LC-MS, GC-MS, CE-MS, and NMR. In contrast, another important class in the intestinal tract are “insoluble” interphase of Bligh–Dyer extraction (Fig. 3A), which includes the strongest inflammatory molecule, bacterial LPS35. Low grade elevation of plasma LPS (metabolic endotoxemia) was found in high fat diet fed mice and humans36,37; therefore, LPS was thought to be an etiologic factor for inducing inflammation-related metabolic syndrome. Thus, further analysis might be required to determine how microbial compositional changes affect inflammatory activities of fecal and plasma LPS.
Although metabolites have been identified, the physiological activities and function of stercobilin in the mammalian body have not been examined. In addition to these metabolites, it is speculated that 3118 small-molecule biosynthetic gene clusters in genomes of human-associated bacteria have been identified38. Therefore, fecal metabolomic analysis can possibly find novel molecules critical in maintaining metabolic homeostasis. Further analyses are required to expand studies using other model animals and human specimens. Because the heme catabolic pathway maybe closely related to lipid metabolism, identification of the transporter for urobilinoids and regulation of bacteria producing urobilinoids by drugs or diet could be therapeutic targets and promising approaches for prevention of lifestyle-related diseases.
Materials and Methods
All animal experiments were approved by the animal ethics committee of the University of Shizuoka (approval number 125005), and performed according to guidelines for the care and use of laboratory animals at the University of Shizuoka. Six-week-old male ob/ob (n = 5) and C57BL/6 J (n = 5) mice were purchased from CLEA Japan, Inc. (Tokyo, Japan). All animals were housed individually in plastic cages and had free access to a basal diet (AIN-76, Oriental Yeast, Co., Ltd., Tokyo, Japan) and tap water under controlled conditions of humidity (55 ± 5%), light (12/12-h light/dark cycle) and temperature (23 ± 1°C). The experimental period was for 24 weeks, following a 1-week adaptation period (Fig. 1A). During the experimental period, mice were placed into a metabolic cage, and their fecal samples were collected at indicated time points. Aliquots of collected feces were immediately stored at −80°C until use. Liver, white adipose tissues and colonic mucosa collected at week 24 were examined by RT-qPCR, hematoxylin–eosin (HE) staining, and immunohistochemistry (IHC). For IHC, frozen sections were treated with HistoVT One (Nakalai tesque, Kyoto, Japan) for of antigen retrieval, and inactivated endogenous peroxidase activity. After the blocking using Blocking One Histo (Nakalai tesque), the sections were incubated with primary antibody (Biotine anti-mouse F4/80 antibody, BioLegend, San Diego, CA). Visualization of antibody binding was performed using Streptavidin-HRP (Abcam, Cambridge, UK) and Histofine DAB Stain kit (Nichirei Corporation, Tokyo, Japan).
NGS 16s sequencing
Microbial DNA in feces was extracted using QIAamp DNA Stool Mini Kit (QIAGEN) and the V1 and V2 variable region of 16 s rRNA was amplified using a specific primer, which consisted of target sequences (V1_F_5′-AGR GTT TGA TYM TGG CTC AG-3′, V1_R_5′-TTA CTC ACC CGT YCG CCR CT-3′, V2_F_5′-AGY GGC GRA CGG GTG AGT AA-3′ and V2_R_5′-TGC TGC CTC CCG TAG GAG T-3′), an adapter, and sample ID discriminating barcodes. The amplicon libraries prepared using the Ion PGM Sequencing 200 kit v2 PGM were loaded onto an Ion 314 chip, then sequenced using the Ion Torrent PGM. (Life Technologies, Carlsbad, CA). Data were analyzed by Ion Reporter (Life Technologies).
Total RNA extracted using a TRIzol reagent (Invitrogen) was converted into cDNA using PrimeScript RT Master Mix (TaKaRa). To quantitatively estimate the level of each gene, quantitative PCR was performed using gene-specific primers, cDNA and SYBR Premix (TaKaRa). The sequences of the PCR primer pairs are as follows: 18 s rRNA; 5′-CTT CTC CAT GTC GTC CCA GT-3′ and 5′-ACG CTG AGC CAG TCA GTG TA-3′, TNF-α; 5′-GAT TAT GGC TCA GGG TCC AA-3′ and 5′-CCC AGC ATC TTG TGT TTC TG-3′, IL-1β; 5′-TCT TCC TAA AAG TAT GGG CTG GA-3′ and 5′-AAA AGG GAG CTC CTT AAC ATG C-3′, IL-6; 5′-CGC TAT GAA GTT CCT CTC TGC-3′ and 5′-TTG GGA GTG GTA TCC TCT GTG-3′, iNOS; 5′-GGT ATG CTG TGT TTG GCC TTG-3′ and 5′-TTC GTC CCC TTC TCC TGT TG-3′, and COX-2; 5′-GGA GGC GAA GTG GGT TTT AAG-3′ and 5′-TTG ATG GTG GCT GTT TTG GTA G-3′
Cell culture and NF-κB assay
Murine macrophage RAW264 cells (RIKEN Cell Bank, Ibaraki, Japan) and human colon cancer HCT116 (RIKEN Cell Bank, Ibaraki, Japan) and HT29 (ATCC) were maintained in 10% FBS/DMEM supplemented with 50 U/ml penicillin and 50 µg/ml streptomycin and grown in an atmosphere of 95% air and 5% CO2 at 37°C. NF-κB reporter gene assay was performed after the transient transfection of pNL3.2 NF-κB-RE vector (Promega) using X-tremeGENE HP DNA Transfection Reagent (Roche). Luciferase activities were evaluated using the Nano-Glo Luciferase assay kit.
Bligh–dyer extraction of feces
Fecal extracts were prepared by the Bligh–Dyer extraction method. Briefly, 30 mg feces suspended in a tube containing 0.5 mg of tert-butylhydroquinone (tBHQ) and 650 µL of MeOH/CHCl3/H2O = 400/200/40 was microdestructed (3000 rpm, 4°C, 120 s ×2 sets) by MicroSmash MS-100R (TOMY, Japan) with a 5.0 φ zirconia (ZrO2) bead. After remove the ZrO2 bead, the tube was centrifuged, and the aqueous and organic phases were harvested in new tubes. Soluble metabolites were extracted again by adding 200 µL of MeOH/CHCl3 = 100/100 to the residue, vortexed, centrifuged, combined with former ones, then dried by a centrifuge evaporator.
Fecal metabolites were analyzed using LC-MS consisting of AQUITY UPLC (Waters, Milford, MA) coupled with micrOTOFQII (Bruker Daltonics, Bremen, Germany). UPLC separation39,40 was performed with a CSH C18 column (1.7 μm, 100-mm × 2.1-mm i.d., Waters) at 40°C, using solvent A (0.1% formic acid in water) and solvent B (MeCN containing 0.1% formic acid). Samples were eluted from the column using a linear gradient of 1% solvent B from 0 to 3 min to 80% solvent B at 20–24 min. The flow rate of the mobile phase was 0.4 ml/min. The TOF-MS was operated in positive and negative ion mode using an electrospray ionization source. The detector conditions were as follows: capillary voltage at 4500 V, nebulizer at 1.6 bar, drying gas flow at 9 l/min, drying gas temperature 200°C, and the mass range between 80 and 2000 m/z. All analyses were performed using a low concentration tuning mix (Agilent Technologies, Palo Alto, CA) to calibrate mass accurately. MS peak data from UPLC-TOF-MS analyses were subjected to Compass Data Analysis (Bruker) and Signpost (Reifycs, Tokyo Japan) for peak detection and integration, and Mass Profiler Professional software (Agilent Technologies) for principal component analysis. For the analysis of plasma levels of stercobilin, plasma samples extracted by methanol were injected into LC-MS/MS consisting of an Agilent 1290 series HPLC coupled with a G6410B triple quadrupole tandem mass spectrometer. HPLC separation was performed with a ZORBAX Eclipse Plus C18 Rapid Resolution HD column (1.8 µm, 50 mm × 2.1 mm, Agilent) at 40°C, using solvent A (0.1% formic acid in water) and solvent B (MeCN containing 0.1% formic acid). Samples were eluted from the column using a linear gradient of 10% solvent B from 0 to 1 min to 80% solvent B at 7 min. The flow rate of the mobile phase was 0.4 ml/min. The MRM transition for stercobilin was monitored at m/z 595.4 > 345.2. In this analytical condition, the detection limit was 1 fmol/injection. Plasma levels of stercobilin were estimated by external standard methods.
All data are presented as the mean ± SEM. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University), a graphical user interface for R (The R Foundation for Statistical Computing). Statistical analyses of data were performed by a t-test or one-way ANOVA followed by Bonferroni’s post hoc test. Differences were considered significant when p < 0.05.
Holmes, E., Li, J. V., Marchesi, J. R. & Nicholson, J. K. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab. 16, 559–64 (2012).
Kinross, J., Li, J. V., Muirhead, L. J. & Nicholson, J. Nutritional modulation of the metabonome: applications of metabolic phenotyping in translational nutritional research. Curr. Opin. Gastroenterol. 30, 196–207 (2014).
Vijay-Kumar, M. et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328, 228–31 (2010).
Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–31 (2006).
Saji, N. et al. Analysis of the relationship between the gut microbiome and dementia: a cross-sectional study conducted in Japan. Sci. Rep. 9, 1008 (2019).
Neufeld, K. M., Kang, N., Bienenstock, J. & Foster, J. A. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol. Motil. 23, 255–64 (2011). e119.
Goswami, C., Iwasaki, Y. & Yada, T. Short-chain fatty acids suppress food intake by activating vagal afferent neurons. J. Nutr. Biochem. 57, 130–135 (2018).
Khan, M. T., Nieuwdorp, M. & Bäckhed, F. Microbial modulation of insulin sensitivity. Cell Metab. 20, 753–760 (2014).
De Vadder, F. et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156, 84–96 (2014).
Chambers, E. S. et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 64, 1744–54 (2015).
Tang, C. et al. Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nat. Med. 21, 173–7 (2015).
McNelis, J. C. et al. GPR43 Potentiates β-Cell Function in Obesity. Diabetes 64, 3203–17 (2015).
Yoshimoto, S. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97–101 (2013).
Tang, W. H. W. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368, 1575–84 (2013).
Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).
Hamoud, A.-R., Weaver, L., Stec, D. E. & Hinds, T. D. Bilirubin in the Liver-Gut Signaling Axis. Trends Endocrinol. Metab. 29, 140–150 (2018).
Wang, X., Chowdhury, J. R. & Chowdhury, N. R. Bilirubin metabolism: Applied physiology. Curr. Paediatr. 16, 70–74 (2006).
Roberts, M. S., Magnusson, B. M., Burczynski, F. J. & Weiss, M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet. 41, 751–90 (2002).
Stec, D. E. et al. Bilirubin Binding to PPARα Inhibits Lipid Accumulation. Plos One 11, e0153427 (2016).
Bixler, J. N. et al. Ultrasensitive detection of waste products in water using fluorescence emission cavity-enhanced spectroscopy. Proc. Natl. Acad. Sci. USA 111, 7208–11 (2014).
Tomaro, M. L., Batlle, A. M. & del, C. Bilirubin: its role in cytoprotection against oxidative stress. Int. J. Biochem. Cell Biol. 34, 216–20 (2002).
Sedlak, T. W. et al. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc. Natl. Acad. Sci. USA 106, 5171–6 (2009).
Belo, L. et al. Body fat percentage is a major determinant of total bilirubin independently of UGT1A1*28 polymorphism in young obese. Plos One 9, e98467 (2014).
Zucker, S. D., Horn, P. S. & Sherman, K. E. Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology 40, 827–35 (2004).
Sekera, E. R. et al. Depletion of Stercobilin in Fecal Matter from a Mouse Model of Autism Spectrum Disorders. Metabolomics 13, (2017).
Kita, Y. et al. The Autism-Related Protein CHD8 Cooperates with C/EBPβ to Regulate Adipogenesis. Cell Rep. 23, 1988–2000 (2018).
Walker, A. et al. Distinct signatures of host-microbial meta-metabolome and gut microbiome in two C57BL/6 strains under high-fat diet. ISME J. 8, 2380–96 (2014).
Kameyama, K. & Itoh, K. Intestinal colonization by a Lachnospiraceae bacterium contributes to the development of diabetes in obese mice. Microbes Environ. 29, 427–30 (2014).
Fahmy, K., Gray, C. H. & Nicholson, D. C. The reduction of bile pigments by faecal and intestinal bacteria. Biochim. Biophys. Acta 264, 85–97 (1972).
Vítek, L., Zelenka, J., Zadinová, M. & Malina, J. The impact of intestinal microflora on serum bilirubin levels. J. Hepatol. 42, 238–43 (2005).
Koníčková, R. et al. Reduction of bilirubin ditaurate by the intestinal bacterium Clostridium perfringens. Acta Biochim. Pol. 59, 289–92 (2012).
Vítek, L. et al. Identification of bilirubin reduction products formed by Clostridium perfringens isolated from human neonatal fecal flora. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 833, 149–57 (2006).
Sticova, E. & Jirsa, M. New insights in bilirubin metabolism and their clinical implications. World J. Gastroenterol. 19, 6398–407 (2013).
Zhang, Y. N., Song, M., Ng, T. B., Zhao, L. & Liu, F. Purification and characterization of antioxidant components from the fruiting bodies of Pleurotus abalonus including 9-beta-d-ribofuranosidoadenine, 5′-deoxy-5′-(methylthio)adenosine, and a triterpenoid. Environ. Toxicol. Pharmacol. 36, 689–696 (2013).
Katz, S. S., Weinrauch, Y., Munford, R. S., Elsbach, P. & Weiss, J. Deacylation of lipopolysaccharide in whole Escherichia coli during destruction by cellular and extracellular components of a rabbit peritoneal inflammatory exudate. J. Biol. Chem. 274, 36579–84 (1999).
Cani, P. D. et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470–81 (2008).
Harte, A. L. et al. High fat intake leads to acute postprandial exposure to circulating endotoxin in type 2 diabetic subjects. Diabetes Care 35, 375–82 (2012).
Donia, M. S. et al. A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics. Cell 158, 1402–1414 (2014).
Miyoshi, N. et al. Development and application of a method for identification of isothiocyanate-targeted molecules in colon cancer cells. Anal. Biochem. 429, (2012).
Hashidume, T. et al. Identification of soybean peptide leginsulin variants in different cultivars and their insulin-like activities. Sci. Rep. 8, 16847 (2018).
We thank Dr. Hiroshi Ohshima for kindly giving critical suggestions. This work was supported in part by a Grant-in-Aid for Scientific Research (KAKENHI, No. 16H03041, and 25560057) from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT, Tokyo).
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sanada, S., Suzuki, T., Nagata, A. et al. Intestinal microbial metabolite stercobilin involvement in the chronic inflammation of ob/ob mice. Sci Rep 10, 6479 (2020). https://doi.org/10.1038/s41598-020-63627-y
o-Anisidine Dimer, 2-Methoxy-N4-(2-methoxyphenyl) Benzene-1,4-diamine, in Rat Urine Associated with Urinary bladder Carcinogenesis
Chemical Research in Toxicology (2021)